Cytosorbents Corporation
CTSO
$1.10
-$0.06-5.17%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -30.53% | -5.10% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -30.53% | -5.10% | |||
| Cost of Revenue | -106.03% | 21.14% | |||
| Gross Profit | 28.20% | -18.78% | |||
| SG&A Expenses | 26.67% | -5.53% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -20.70% | 4.53% | |||
| Operating Income | -0.61% | -33.97% | |||
| Income Before Tax | -310.21% | 43.66% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -237.77% | 43.66% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -237.77% | 43.66% | |||
| EBIT | -0.61% | -33.97% | |||
| EBITDA | -0.51% | -39.40% | |||
| EPS Basic | -235.90% | 43.77% | |||
| Normalized Basic EPS | -332.95% | 42.76% | |||
| EPS Diluted | -235.90% | 43.77% | |||
| Normalized Diluted EPS | -332.95% | 42.76% | |||
| Average Basic Shares Outstanding | 0.48% | 0.27% | |||
| Average Diluted Shares Outstanding | 0.48% | 0.27% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||